Kenneth Oye
机构: Professor of Political Science and Data, Systems and Society, MIT
每年引用次数
引用次数
引用: 7,149
H-指数: 29
I10-指数 : 54
出版物: 90
Public environmental regulation and private business risk : improving corporate strategies and regulatory policies
Niclas Adler , T Bernauer , C Pitelis , J Foster
2004
Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need.
G Hirsch , M Trusheim , E Cobbs , M Bala
Clinical Pharmacology & Therapeutics 100 ( 6) 685 -698
6
2016
From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.
H‐G Eichler , LG Baird , R Barker , B Bloechl‐Daum
Clinical Pharmacology & Therapeutics 97 ( 3) 234 -246
136
2015
Adaptive licensing: taking the next step in the evolution of drug approval.
J Sobotka , D Tan , T F Unger , G Hirsch
Clinical Pharmacology & Therapeutics 91 ( 3) 426 -437
219
2012
Corrigendum: Adaptive biomedical innovation: Evolving our global system to sustainably and safely bring new medicines to patients in need
G Hirsch , M Trusheim , E Cobbs , M Bala
Clinical Pharmacology & Therapeutics 101 ( 4) 542 -542
2017
Regulatory Diversity: Can the World Trading System Cope
Thomas Bernauer , K Oye , David G Victor
Swiss Political Science Review 6 ( 3) 96 -108
6
2000
Creating a research agenda for the ecological implications of synthetic biology
Kelly Drinkwater , T Kuiken , S Lightfoot , J McNamara
MIT Center for International Studies, Cambridge, MA, and Woodrow Wilson International Center for Scholars, Washington, DC
20
2014
Legal foundations of adaptive licensing: legal foundations of adaptive licensing 3 April 2012 european medicines agency, canary Wharf, London, UK
K Oye , LG Baird , A Chia , S Hocking
Clinical Pharmacology & Therapeutics 94 ( 3) 309 -311
16
2013
Nutzenbewertung für Untersuchungs-und Behandlungsmethoden mit Medizinprodukten hoher Klassen: Die Abwägung von Patientennutzen, Evidenz und Zugang
Axel C Mühlbacher , Christin Juhnke ,
Das Gesundheitswesen 80 ( S 02) S80 -S87
11
2018
Studien bei seltenen Erkrankungen: eine deskriptive Analyse abgeschlossener Orphan Drug Bewertungen im Gemeinsamen Bundesausschuss
Sandra Schulz , Anna Passon , Michael Kulig , Matthias Perleth
Das Gesundheitswesen 80 ( 12) e54 -e61
6
2018